Author: Asaf Poran; Dewi Harjanto; Matthew Malloy; Michael S. Rooney; Lakshmi Srinivasan; Richard B. Gaynor
Title: Sequence-based prediction of vaccine targets for inducing T cell responses to SARS-CoV-2 utilizing the bioinformatics predictor RECON Document date: 2020_4_8
ID: 54mx8v4i_27
Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.06.027805 doi: bioRxiv preprint CoV-2 that had previously been assayed in ViPR were confirmed as non-binding. We therefore 1 concluded that using RECON's HLA binding predictors to predict T cell epitopes from the ORFs 2 of SARS-CoV-2 provides a significantly expanded, novel set of high-quality vaccine targets for 3 the virus. These sequen.....
Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.06.027805 doi: bioRxiv preprint CoV-2 that had previously been assayed in ViPR were confirmed as non-binding. We therefore 1 concluded that using RECON's HLA binding predictors to predict T cell epitopes from the ORFs 2 of SARS-CoV-2 provides a significantly expanded, novel set of high-quality vaccine targets for 3 the virus. These sequences can be exploited for vaccines in various formats, including RNA or 4 peptides. 5 6 This application of our prediction algorithms has clearly identified many candidate epitopes that 7 can be included in a vaccine to induce cellular responses against this novel virus. Immune Although short lived, antibody responses are essential to control the persistent phase of CoV 16 infection by preventing subsequent viral entry. We thus propose that a combination of B and T 17 cell epitopes could provide long-lasting immunity from SARS-CoV-2 or mitigate the severity of 18 disease when protection is partial. 19 The strength of our prediction is two-fold: first, we have validated predictors for both HLA-I and 20 HLA-II binders, which potentially could be leveraged to induce both long-term CD4 + and CD8 +
Search related documents:
Co phrase search for related documents- antibody response and cell epitope: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- antibody response and cellular response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- antibody response and high quality: 1, 2, 3, 4, 5
- antibody response and long last: 1, 2
- antibody response and long last immunity: 1
- antibody response and long term: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- antibody response and novel set: 1, 2, 3
- antibody response and novel virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- antibody response and persistent phase: 1
- antibody response and prediction algorithm: 1
- antibody response and subsequent viral entry: 1
- antibody response and vaccine target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- antibody response and viral entry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- candidate epitope and cell epitope: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- candidate epitope and cellular response: 1, 2, 3, 4, 5, 6, 7
- candidate epitope and long term: 1
- candidate epitope and novel virus: 1, 2
- candidate epitope and vaccine target: 1, 2
- cell epitope and high quality: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date